• Revenue up 28.4% to $124.8M
• Profit after tax up 230.9% to $171.2M
• Signed 7 new contracts worth over A$280M

Pro Medicus Ltd. (ASX:PME) has reported its financial results for the first half of FY26, delivering a record performance. Revenue increased by 28.4% to $124.8 million, while profit after tax surged 230.9% to $171.2 million. The company's underlying EBIT grew by 29.7% to $90.7 million, with EBIT margins reaching 72.6%. Pro Medicus' cash and investments also increased by 5.3% to $221.8 million, and the company remains debt-free with a strong balance sheet. The company declared an interim dividend of $0.32 per share, up 28% from the previous year. Key highlights for the half-year include signing seven new contracts worth over A$280 million, renewing a A$20 million contract with FMOL, and securing a large cardiology sale to the University of Colorado. The company also completed six cloud-based implementations and made significant progress in expanding into new 'ologies' and AI-related offerings. Pro Medicus' operational model, based on transaction minimums, has resulted in a forward revenue pipeline of over A$1.08 billion over the next five years. The company's investment in 4DMedical (ASX:4DX) has also generated an unrealized gain of approximately $150 million as of December 31, 2025. Pro Medicus continues to expand its footprint in the Integrated Delivery Network (IDN) market, with recent IDN sales including multiple Visage products in a 'full stack' solution. The company has also seen renewed interest in the private market segment, securing a A$44 million, 5-year deal with RANT. In Australia, Pro Medicus has secured long-term contracts with the two largest radiology providers, Lumus and I-MED, and is seeing increased market interest with new opportunities. The company's Visage 7 platform, known for its speed, functionality, and scalability, is well-positioned to address the growing demand for enterprise imaging solutions driven by the explosion of medical imaging data. Pro Medicus' growth strategy includes expanding its footprint, driving transaction growth from existing clients, developing new product offerings, extending into new geographical markets, and leveraging its R&D capabilities to introduce next-generation products. The company remains well-placed to benefit from the adoption of AI in the healthcare sector, with its in-house AI development capabilities and research collaborations.

Pro Medicus has reported a forward revenue pipeline of over A$1.08 billion over the next five years, based on the assumption that key contracts up for renewal are renewed.

Pro Medicus is well-positioned to continue its growth trajectory, with a robust pipeline of opportunities, a strategic advantage in the cloud-based enterprise imaging market, and the ability to leverage its technology leadership and AI capabilities to drive further expansion.